Not approved by the TGA for therapeutic use
doi: 10.3389/fendo.2025.1541794
If you do have access to weights, even two or three sessions per week can make a meaningful difference
Scope: Comprehensive review of ANGPTL3 inhibition as a therapeutic strategy to reduce triglyceride-rich lipoproteins and residual cardiovascular risk Therapeutic approaches discussed: Monoclonal antibodies (e.g., evinacumab) RNA-based therapies (ASOs and siRNA: vupanorsen, zodasiran, solbinsiran) Emerging gene-editing strategies (CRISPR/base editing) Key message: Targeting ANGPTL3 provides robust reductions in triglycerides, apoB-containing lipoproteins, and non-HDL cholesterol, independently of the LDL receptor Clinical relevance: Positions ANGPTL3 inhibition as a next-generation approach for managing mixed dyslipidemia and lipid-related residual risk beyond LDL-C Laura Schreier Natalia Nardelli European Atherosclerosis Society To view or add a comment, sign in Tipping the Scale in MASH: The TZD vs
barbarum may not accumulate these compounds at concerning levels
Source: Cherry Orange Ingredients: 74,7% L-Carnitine L-Tartare, aromas, maltodextrin, colouring E 150d (for all cola flavours)
